Controversy

Whether amino-acid PET (FET/FDOPA/MET) should be standard-of-care adjunct for progression/recurrence vs remains access-limited and under-validated

Evidence grade: WEAK — Supported only by weak or preliminary evidence.

computed from the encoded evidence by the Atlas grading rule.

Position A

PET-RANO/RANO working group and reviews support amino-acid PET for treatment-response and recurrence assessment

Position B

Evidence is largely single-center, heterogeneous thresholds, limited availability; prospective outcome-linked validation sparse

Clinical stakes

Could resolve pseudoprogression problem but access and standardization limit reach

Open in the interactive atlas →

About this page

Curated and maintained by Resonant Labs. Reviewed by Claims are synthesized from the cited literature and graded per the Atlas methodology (about the Atlas). Last updated 2026-07-01.

This is an educational research resource from Resonant Labs, not clinical advice. Evidence grades and controversies are summarized from the literature and may change as the field evolves.